2-(4,5-diphenyl-2-oxazolyl)-3'-benzyloxybenzhydrol | 171046-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4,5-diphenyl-2-oxazolyl)-3'-benzyloxybenzhydrol
• 英文别名: [2-(4,5-diphenyl-1,3-oxazol-2-yl)phenyl]-(3-phenylmethoxyphenyl)methanol
• CAS: 171046-77-8
• 化学式: C₃₅H₂₇NO₃
• 分子量: 509.604
• InChiKey: UWNAZUNYSFZTOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  55.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4,5-diphenyl-2-oxazolyl)-3'-benzyloxybenzhydrol 在 palladium on activated charcoal 盐酸 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 Methyl [3-[[2-(4,5-diphenyl-2-oxazolyl)phenyl]-methyl]phenoxy]acetate
  参考文献：
  名称：

  Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6

  摘要：

  The synthesis and biological activity of novel derivatives of our previously reported IP receptor agonist FR181157 is described. SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of compound 1i (FR207845) as a potent non-prostanoid PGI(2) mimetic with good oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.076
• 作为产物：
  描述：

  2-Oxo-1,2-diphenylethyl 2-bromobenzoate 在 ammonium acetate 、 magnesium 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 生成 2-(4,5-diphenyl-2-oxazolyl)-3'-benzyloxybenzhydrol
  参考文献：
  名称：

  Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6

  摘要：

  The synthesis and biological activity of novel derivatives of our previously reported IP receptor agonist FR181157 is described. SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of compound 1i (FR207845) as a potent non-prostanoid PGI(2) mimetic with good oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.076

文献信息

• 4,5-diaryloxazole derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06025375A1

  公开（公告）日：2000-02-15

  Heterocyclic compounds of the formula: ##STR1## whereinR.sup.1 is carboxy or protected carboxy, R.sup.2 is aryl which may have suitable substituent(s), R.sup.3 is aryl which may have suitable substituent(s), A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene and -Q- is ##STR2## etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.

  式为：##STR1##其中R.sup.1是羧基或保护羧基，R.sup.2是芳基，可能有适当的取代基，R.sup.3是芳基，可能有适当的取代基，A.sup.1是较低的烷基，A.sup.2是键或较低的烷基，-Q-是##STR2##等，以及其药学上可接受的盐，可用作药物。
• 4,5-DIARYLOXAZOLE DERIVATIVES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0736018B1

  公开（公告）日：2000-07-05
• US6025375A
  申请人：——

  公开号：US6025375A

  公开（公告）日：2000-02-15
• [EN] 4,5-DIARYLOXAZOLE DERIVATIVES<br/>[FR] DERIVES DE 4,5-DIARYLOXAZOLE
  申请人：FUJISAWA PHARMACEUTICAL Co., LTD.

  公开号：WO1995017393A1

  公开（公告）日：1995-06-29

  (EN) Heterocyclic compounds of formula (I) wherein R1 is carboxy or protected carboxy, R2 is aryl which may have suitable substituent(s), R3 is aryl which may have suitable substituent(s), A1 is lower alkylene, A2 is bond or lower alkylene and -Q- is (II), etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.(FR) Composés hétérocycliques de formule (I) dans laquelle R1 représente carboxy ou carboxy protégé, R2 représente aryle à un ou plusieurs substituants appropriés, R3 représente aryle à un ou plusieurs substituants appropriés, A1 représente alkylène inférieur, A2 représente une liaison ou alkylène inférieur et -Q- représente un groupe (II), etc., et sels pharmaceutiquement acceptables desdits composés, qui sont utiles en tant que médicament.
• Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6
  作者：Akira Tanaka、Kouji Hattori、Kiyoshi Taniguchi、Osamu Okitsu、Seiichiro Tabuchi、Mie Nishio、Yasunori Nagakura、Noriaki Maeda、Hidetsugu Murai、Jiro Seki

  DOI：10.1016/j.bmcl.2006.06.076

  日期：2006.9

  The synthesis and biological activity of novel derivatives of our previously reported IP receptor agonist FR181157 is described. SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of compound 1i (FR207845) as a potent non-prostanoid PGI(2) mimetic with good oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.